Saturday, 28 February 2009

Fondaparinux Sodium




Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

B01AX05

CAS registry number (Chemical Abstracts Service)

0114870-03-0

Chemical Formula

C31-H43-N3-Na10-O49-S8

Molecular Weight

1728

Therapeutic Category

Anticoagulant agent: Selective inhibitor of blood-coagulation factor Xa

Chemical Name

Methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-ß-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-OR-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyrano (WHO)

Foreign Names

  • Fondaparinuxum natricum (Latin)
  • Fondaparinux natrium (German)
  • Fondaparinux sodique (French)
  • Fondaparinux sodico (Spanish)

Generic Names

  • Fondaparinux Sodium (OS: BAN, USAN)
  • Fondaparin sodium (IS)
  • Fondaparinux (IS)
  • IC 851589 (IS)
  • Org 35140 (IS: Organon)
  • Pentasaccharid Faktor Xa-Inhibitor (IS: selektiv)
  • SR 90107A (IS: SanofiSynthela)
  • Xantidar (IS)

Brand Names

  • Arixtra
    Glaxo Group, Austria; Glaxo Group, Iceland; Glaxo Group, Luxembourg; Glaxo SmithKline, Spain; GlaxoSmithKline, Antigua & Barbuda; GlaxoSmithKline, Netherlands Antilles; GlaxoSmithKline, Australia; GlaxoSmithKline, Aruba; GlaxoSmithKline, Barbados; GlaxoSmithKline, Belgium; GlaxoSmithKline, Bermuda; GlaxoSmithKline, Bahamas; GlaxoSmithKline, Canada; GlaxoSmithKline, Switzerland; GlaxoSmithKline, China; GlaxoSmithKline, Colombia; GlaxoSmithKline, Costa Rica; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Dominican Republic; GlaxoSmithKline, Finland; GlaxoSmithKline, France; GlaxoSmithKline, United Kingdom; GlaxoSmithKline, Grenada; GlaxoSmithKline, Guatemala; GlaxoSmithKline, Guyana; GlaxoSmithKline, Honduras; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Hungary; GlaxoSmithKline, Indonesia; GlaxoSmithKline, Italy; GlaxoSmithKline, Jamaica; GlaxoSmithKline, Cayman Islands; GlaxoSmithKline, Saint Lucia; GlaxoSmithKline, Mexico; GlaxoSmithKline, Malaysia; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Norway; GlaxoSmithKline, Panama; GlaxoSmithKline, Peru; GlaxoSmithKline, Portugal; GlaxoSmithKline, Russian Federation; GlaxoSmithKline, Sweden; GlaxoSmithKline, Singapore; GlaxoSmithKline, Slovenia; GlaxoSmithKline, Slovakia; GlaxoSmithKline, El Salvador; GlaxoSmithKline, Thailand; GlaxoSmithKline, Turkey; GlaxoSmithKline, Trinidad & Tobago; GlaxoSmithKline, United States; GlaxoSmithKline, South Africa; Sanofi-aventis, Greece; Sanofi-aventis, Oman


  • Quixidar
    GlaxoSmithKline, Slovakia

International Drug Name Search

Glossary

BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

No comments:

Post a Comment